Introduction
To understand the basic mechanism of acquired drug resistance, an ovarian cancer cell line (A2780/100) was developed by exposing the parental cell line (A2780) to escalating doses of an alkylating agent, chlorambucil (Cbl).
1 A2780/ 100 cells are 10-fold more resistant (on the basis of lethal dose 50 (LD 50 ) values) than the parental cell line to the cytotoxic effect of Cbl, as measured by loss of the colony-forming ability of cells.
1,2 Cbl-resistant A2780/100 cells also show cross-resistance to cisplatin (Cpl), bis-chloronitrosourea (BCNU), melphalan and ionizing radiation. Drug resistance is associated with increased expression of antiapoptotic proteins, BCL2L1, Mcl-1 and decreased expression of Bax, a known proapoptotic protein and glutathione S-transferase (GSTp). Modulation of BCL2L1, Bax and GSTp by transgenic overexpression or gene silencing does not significantly alter resistance to Cbl, Cpl or etoposide, indicating that the primary mechanism of drug resistance in A2780/100 cells is not due to enhanced drug detoxification or enhanced expression of antiapoptotic proteins. 1, 2 Cbl first induces DNA monoalkyl adducts, followed by alkyl cross-links. However, Cbl resistance of A2780/100 cells does not elevate the expressions of N-methylpurine-DNA glycosylase, O-6-methylguanine-DNA methyltransferase, ERCC-4 2,3 or base excision repair proteins such as APE1 and DNA b-polymerase 3 in these cells. Various strategies can be used to sensitize resistant cancer cells to develop successful and improved therapy. 4, 5 Reactive oxygen species (ROS), by-products of metabolisms, are toxic to cells, but can also exert its effect as signaling molecules leading to the regulation of many cellular processes, including metabolism, cell-cycle control and DNA repair. 6 ROS indeed has a role in the alteration of the activity of protein kinases (for example, p38 mitogen-activated kinases, Jun N-terminal kinases, extracellular signalregulated kinase) 7 and p53. 8 By modulating endogenous ROS, colon cancer cells have been sensitized 9, 10 and Mookerjee et al. 11, 12 sensitized leukemia cell lines with copper (N-2-hydroxyacetophenone) glycinate, 11 which increases ROS. Earlier observations indicate that reduced level of ROS in A2780/100 cells is one of the principal reasons for developing and maintaining Cbl resistance. In this study, these A2780/100 Cbl-resistant cells were sensitized with very low doses of exogenous COS (chronic oxidative stress). Using microarray gene expression, I studied the probable molecular mechanisms of sensitizing A2780/100-resistant cells and the involvement of key regulator genes, DNA-PKc, ARHGEF6, NF-kB2 (p52) and HSP70, in the apoptotic signaling pathway in Cbl cos cells. Unfolding the molecular mechanism of drug resistance in these cells may help to develop strategies for sensitization of ovarian carcinoma cells and subsequently for future chemotherapy.
Material and methods

Cell culture and drug treatment
Human ovarian carcinoma A2780-and A2780/100-resistant cells are maintained in RPMI 1640 (Gibco-Invitrogen Inc., Carlsbad, CA, USA) with 10% fetal bovine serum (FBS; Sigma-Aldrich, St Louis, MO, USA), glutamine (292 mg l À1 ), penicillin (100 U ml À1 ) and streptomycin (100 mg ml À1 ) at 37 1C in a humidified 5% CO 2 atmosphere. Cells are treated for 1 h at 37 1C with Cbl (100 mM) (Sigma-Aldrich; freshly dissolved in methanol/hydrochloric acid (49:1), washed with phosphate-buffered saline (PBS) and put in a fresh medium). To generate COS, I added a low dose of glucose oxidase (GO; 10 ng ml À1 (0.0026 U ml À1 ); USB, Cleveland, OH, USA) to Cbl-treated cells after 1, 3, 6 and 9 h and, in some cases, after 12 h. Cell death is observed and counted after 24 h.
Clonogenic survival assay
Clonogenic survival assays are carried out as described previously. 2 Briefly, 200 cells in each 60 mm dish are allowed to attach for about 4 h, exposed to increasing concentration of Cbl for 1 h, followed by addition of growth media containing 10% FBS. Nontoxic doses of H 2 O 2 , GO and NOO À are added at 1, 3, 6 and 9 h after Cbl treatment. Colonies are fixed and stained using cocktail buffer containing 2% (w/w) of formaldehyde (Fisher Scientific, Austin, TX, USA) and 0.01% (w/v) of crystal violet (Sigma-Aldrich). Relative cell survival is calculated from the number of colonies per dish.
Annexin V apoptotic assay
To identify apoptotic cells, performed flow cytometric analysis on cells stained with Annexin V/PE (phycoerythrin) and 7-amino actinomycin D (7-AAD). 13 Briefly, cells were trypsinized, washed in PBS and resuspended in cold Annexin V binding buffer (10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.4), 0.14 mM NaCl, 0.25 mM CaCl 2 Â 2H 2 O, 0.1% bovine serum albumin (BSA; w/v). Annexin-PE (BD Biosciences, San Jose, CA, USA) was added to cells for 30 min and then 7-AAD (2 mg ml À1 ) was added before analysis in a FACScan flow cytometer (Becton Dickinson, Franklin Lake, NJ, USA). The mean fluorescence for 12 000 cells from three or more independent experiments is expressed as ±s.e.m.
RNA isolation and hybridization with affymetrix human genomic chips
Total RNA is isolated with Trizol (Invitrogen, Carlsbad, CA, USA) and subjected to DNAse1 digestion to remove any traces of DNA contamination. RNA is further purified using an RNAeasy column (Qiagen, Valencia, CA, USA). Microarray hybridizations and scanning are carried out in core facility. The quality of RNA is determined by Agilent 2100 Bioanalyzer Agilent Technology, Santa Clara, CA, USA. From 10 mg of total RNA of each sample, first-strand and doublestrand cDNAs are synthesized using the Superscript FirstStrand Synthesis kit (Invitrogen) and Escherichia coli DNA polymerase, respectively, and blunt ended with T4 DNA polymerase. Biotinylated cRNA probes are synthesized using an in vitro transcription kit (Enzo Laboratories; Applied Biosystems, Foster City, CA, USA). Each 15 mg of biotinylated cRNA probe is fragmented to approximately 100 bp using a fragmentation buffer (Applied Biosystems) and used for hybridization. Human genomic chip U_95AV2 containing approximately 10 000 full-length genes (Affimetrix Inc., Santa Clara, CA, USA) is hybridized with 15 mg of fragmented biotinylated cRNA probe. Hybridized chips are scanned using Gene Array Scanner (Hewlett Packard, Palo Alto, CA, USA).
Statistical analysis
Hybridized scanned data are analyzed using two softwares, Spotfire Array Explorer version 7 (Spotfire Inc., Cambridge, MA, USA) and GeneSpring (Silicon Genetics, Santa Clara, CA, USA). Genes are analyzed as present and marginal criteria. Normalized genes (those above background and corrected with the internal chip control) are filtered on the basis of expression level and 6126 genes those passed the criteria are further analyzed. These filtered genes are subjected to build two-way analysis of variance (ANOVA) 
Western blotting
Pelleted cells are lysed in lysis buffer. After centrifugation, protein concentrations are determined using the Bradford reagent (Bio-Rad Inc., Hercules, CA, USA). Total protein (50 mg) is loaded onto a 6 or 10% (6% for DNA-PKc) SDS gel and transferred to polyvinylidene difluoride membrane (Immobilon, Millipore), blocked with 5% dry milk in PBS-T (25 mM Tris-HCl (pH 8.0), 125 mM NaCl and 0.025% Tween 20) for 1 h at room temperature and incubated with appropriate primary antibodies (anti-DNA-PKc; BD Pharmingen, San Diego, CA, USA; anti-NF-kB2/p52, Upstate Biotechnology; anti-ARHGEF6, Orbigen Biotechnology; anti-HSP70, anti-BCL2L1 and anti-p53, anti-actin and antitubulin are from Santa Cruz Biotechnology) for 90 min, washed thoroughly, followed by incubation with horseradish-peroxidase-conjugated secondary antibody (Amersham Inc., Fairfield, CT, USA; 1:500 to 1:1000 dilution) for 1 h. Secondary antibody is detected by enhanced chemiluminescence (Amersham Inc.). Protein bands of western blots are scanned and quantitated with ImageQuant software, Silk Scientific, Orem, Utah, USA. The ratio of a given protein band to the area of its corresponding b-actin band is taken into account for protein quantitation and a bar diagram is shown for each protein to visualize the fold change. 
Co-immunoprecipitation and immunocytochemistry
Results
Chronic subtoxic oxidative stress sensitizes A2780/100 to Cbl Chlorambucil-treated A2780 cells continuously generate ROS, whereas A2780/100-resistant cells normalize ROS level after the first 2 h of treatment; this observed decrease in ROS in resistant cells may be attributed to glutathione extrusion from the cell.
14 Therefore, the inability of cells to maintain oxidative stress may be the reason for the observed resistance in A2780/100 cells. 15 When A2780/100 cells are treated with L-buthionine (SR)-sulfoximine (BSO), a g-glutamylcysteine synthetase (a rate-limiting enzyme in glutathione (GSH) synthesis) inhibitor, 16 the percentage of cell survival significantly decreased. LD 50 of Cbl A2780/100 cells also decreases when cells are exposed to GSH-depleting agent, diethyl maleate. 16 In this study, ROS produced in GSH-depleted cells is H 2 O 2 because GSH is a substrate for GSH peroxidase to eliminate H 2 O 2 .
14 Accordingly, 5 mM H 2 O 2 , a signaling and growth stimulatory 17 dose, is added 50 .
To further assess the impact of low-dose COS on Cblmediated cytotoxicity, COS is generated by GO treatment (10 ng ml À1 , 0.0026 U ml À1 ). GO, a high molecular weight protein, generates H 2 O 2 when it reacts with glucose, 18, 19 which in turn produces superoxide anion (O 2 À ), which is converted by dismutases (Cu/ZnSOD to MnSOD and FeSOD) into H 2 O 2 . 20 As determined in preliminary studies, a dose of GO (10 ng ml À1 , 0.0026 U ml
À1
) causes an approximately twofold increase in intracellular levels of ROS and gives more consistent oxidative insult than does H 2 O 2 alone. Moreover, exogenous addition of 1 nM NOO À (generated by diethylamine NONOate), but not NO, sensitizes A2780/100 cells to Cbl, which can be reversed by a peroxinitrite scavenger, MCP (3-methyl-1,2-cyclopentanedione; bar 9, Figure 1a ). In parallel experiments, multiple doses of COS do not affect survival of control solvent-treated cells. The cells treated with LD 50 dose of Cbl under COS conditions exhibit apoptosis, which is shown by the detection of cellsurface expression of phosphatidyl-D-serine on the outer leaflet using Annexin V assay. 13 When only Cbl or multiple doses (3-5) of COS are added separately, it neither causes Annexin V binding nor has an impact on cell survival colony formation assays (data not shown). Similarly, extensive cell death of A2780/100 cells is not observed by treating with COS multiple times and then once with Cbl (100 mM) (75% cell death is observed; data not shown). These results suggest that Cbl-resistant A2780/100 cells are sensitive to exogenous COS and sublethal doses of COS can kill these cells.
Gene expression profiling of A2780/100 cells treated with chlorambucil and chronic oxidative stress To elucidate the molecular mechanism of COS-mediated increase in Cbl sensitivity of A2780/100 cells, we performed microarray hybridizations with Affymetrix oligo chips. A2780/100 cells are treated with GO (0.0026 U ml À1 ), 21 Cbl (25 mM, 2 Â LD 50 ) or Cbl (25 mM) with COS (10 ng ml À1 at 1, 3 and 6 h after Cbl exposure). Total RNAs are isolated at 0, 4 and 9 h after Cbl exposure and used for microarray hybridization. As control, RNA is isolated from actively replicating nontreated A2780 cells. Analysis with two software indicates that A2780 and A2780/100 cells have a different expression profile (Supplementary Figure 1A) . Differential expression in drug-resistant A2780/100 cells over Cbl-sensitive cells suggests that a set of genes may contribute to Cbl resistance. Although only COS-treated A2780/100 cells have a very different gene expression profile, significant differences in expression profile are observed between Cbl-and Cbl cos -treated cells. By K-means (K ¼ 5) cluster analysis, similarly expressed genes are grouped. Global changes of repair, channel, mitochondrial and apoptotic genes are particularly shown (Supplementary Figure 1B) . By two-way (treatment and time) ANOVA building and Gene Tree classification, a number of genes (at 95% confidence level) are further identified that are (Figure 1b ) and signals cell death by apoptosis, as earlier evidenced in Cbl-treated A2780-sensitive cells. 2, 15 Expression profiling of Cbl-sensitive A2780 and -resistant A2780/100 cells shows the expression difference for a set of genes, and those changes in gene expression due to Cbl-induced resistance in A2780/100 cells are not apparent. Validation of microarray gene expression by real-time PCR Among differentially regulated genes, five genes (CDK6, CLARP2, TSPYL4, RYBP and CYR61) are selected and their mRNA expressions are validated by real-time PCR (TaqMan method). A cyclin-dependent kinase, CDK6, helps maintain a higher ROS level and its reduced expression leads to cell-cycle arrest and promotes apoptosis. 22 Although CDK6 is highly expressed in only Cbl-treated cells, an almost threefold reduction in the expression level of CDK6 at 4 and 9 h in Cbl cos cells may mediate cell-cycle arrest and apoptosis (Figure 2a) .
TSPYL4 is a nucleosome assembly protein and may have a role in gene regulation by histone accessibility. 23 However, increased expression of TSPYL4 in Cbl cos -treated cells may have an unknown significance that remains to be explored. A death-effective domain-containing protein, CLARP2, interacts with caspase-8 and regulates apoptosis. 24 This stress-sensitive gene shows a decreased expression of fourfold at 4 h and twofold at 9 h (Figure 2a ) in Cbl cos -treated cells than in Cbl-treated cells and implicates its role in apoptotic signaling as observed in other cells. 24 RYBP, a ryanodine-binding protein, bears a death effector domain (DED) that is crucial for apoptotic signaling. Increase in RYBP can trigger DEDAF (DED-associated factor)-mediated apoptosis. 25 Its expression level is twofold higher at 9 h in Cbl-, COS-and Cbl cos -treated cells than in A2780 and A2780/100 cells. Its higher expressions in Cbl cos -treated cells are maintained at both 4 and 9 h, whereas it is reduced at 9 h in Cbl-treated cells, suggesting that the twofold higher level of expression of this gene may also be necessary for apoptosis signaling in Cbl cos -treated cells. An apoptotic inducer in tumor cells, Cyr61, is highly expressed in only COS-treated cells and its stress-sensitive expression has not been reported earlier. However, its expression level is elevated at 4 h but decreased significantly (sixfold) in Cbl-and Cbl cos -treated cells at 9 h.
Differential expression of apoptotic signaling genes at protein levels because of Cbl cos treatment It would be important to correlate whether transcript and protein levels of ARHGEF6, p53, NF-kB2/p52 and HSP70 are also differentially regulated and contribute to apoptotic cell death of Cbl cos -treated cells. Guanine nucleotide depletion triggers cell-cycle arrest and apoptosis in human neuroblastoma cells. 26 ARHGEF6, a cdc42 guanine exchange factor, mutated in human nonspecific mental retardation, interacts with paxillin, which is involved in cell proliferation, spreading and regulating contact inhibition through integrin-mediated cell signaling. 27 Its transcript and protein levels decrease twofold (Figures 3a and b (Figures 3c and d) . Moreover, p53 interacts with DNA-PKc in both Cbl-and Cbl cos -treated cells (Figure 3g ). Subsequent immunocytochemistry analyses show that p53 protein is extruded from the nucleus to the cytoplasm (Supplemetary Figures 2III and IV) in Cbl cosinduced cells, whereas in Cbl-treated cells, the p53 protein is mostly localized in the nucleus. Regardless of the mechanism, the differential expressions of p53-dependent genes (TIEG1, CACNA2D2, TRAF3 and the recently described Cbl with COS kills Cbl-resistant ovarian carcinoma cells
Discussion
Understanding the mechanisms by which tumor cells maintain resistance is important for improving the therapeutic management of human malignancies. In this study, I report that chronic nontoxic doses of ROS can selectively increase drug efficacy and reverse multidrug resistance of ovarian A2780/100 carcinoma cells, although Cbl or COS alone is unable to sensitize Cbl-resistant cells. Sensitization to Cbl with COS has not been reported earlier, however, moderate levels of ROS are shown to be important in redox regulation and activation of caspases concomitantly in apoptosis. [33] [34] [35] Although the role of ROS is unknown, it could affect the activity of DNA repair pathways or may be synergistic with drugs in promoting cell death through the activation of proapoptotic p53. 8 COS, along with Cbl, is expected to increase or sustain DNA damage in A2780/100 cells. Noncytotoxic doses of H 2 O 2 have the potential to confer its cytotoxic effect in two ways: (1) H 2 O 2 may directly confer its cytotoxic activity with other stronger ROS (see review, see Ferriero 36 ) or may increase the penetration and accumulation of Cbl into Cbl cos cells; (2) extensive DNA damage may be responsible for the inhibition of tumorigenicity and may regulate apoptosis. However, my observations of a differential gene expression of DNA damage-inducible and repair genes, cell growth retardation signaling genes and apoptotic genes support later explanations. Moreover, three major cellular events are necessary for cell death in Cbl cos cells: (1) excessive DNA damage and breakdown of genomic integrity; (2) inhibition of oncogenic progress, that is, to stop proliferation and cell adhesion, suppression of angiogenic processes, growth retardation and arrest; (3) signaling to apoptosis. A diagram depicting the probable mechanism of cellular death by Cbl cos is constructed using IPA analysis (Figure 1b) . It is more likely that one or few master regulatory genes are more activated in CBl cos cells compared to Cbl cells and exert its effect on apoptotic and death pathway genes to signal apoptosis. Hence, the expression differences of many genes in these two cells may be more of a secondary effect rather than of a regulatory effect. Several proteins involved in apoptotic signaling pathways (NF-kB2, ARHGEF6, TRAF3 and TIEG1 for JNK, BCL2L1, CACNA2D2; Figures 2a and b, 3, 4) and cell death-mediated pathways (caspase-8, caspase-9, FADD, MORT) are differentially regulated. However, recently it has been suggested that apoptosis generally occurs through mitochondria, 37 although more evidence is needed to propose a common pathway.
Chlorambucil-induced alkylation of DNA results predominantly in N7-guanine adducts and yields apurinic sites, which in turn can cause strand breaks and breaks of cross-links. 38 Repair of DNA cross-links may involve double-stranded break intermediates through a nonhomologous end-joining process, and it require the DNA-PKcs complex, a catalytic subunit of DNA-PKc, the Ku70 and Ku86 heterodimers. Earlier it was shown that DNA-PKcs do not change significantly after Cbl treatment until 3 h of treatment, but reduction of kinase activity was observed in Cbl cos -treated drug-sensitive cells. 15 It is possible that after COS treatment in Cbl-treated drug-resistant cells, DNA-PKcs catalytic subunit is degraded by caspases, 29 as previously shown in other tumor cells.
Reduced expression of ARHGEF6, CDK6 and TIEG1 at early stage and of CYR61 at late stage may also contribute toward the inhibition of proto-oncogenic activity. Very recently, Cbl -9h Cbl -9h Cbl -12h Cbl -12h A27/100 -NT A27-Cbl -4h A27-Cbl -9h A27/100 -NT A27/100 -Cbl-4h A27/100 -cos-4h A27/100 -cos-9h A27/100 -Cbl-9h A27/100 -Cbl-4h A27/100 -cos-4h downregulation of cyr61, which is shown to potentiate the anticancer activity of zoledronic acid in prostate cancer, 39 justifies its reduction in Cbl and Cbl cos cells. ARHGEF6, a Gcoupled receptor activated by phosphatidylinositol 3-kinase, modulates the cellular ROS level through Rac1. It also modulates ROS production from nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity in a growth factor-dependent manner, 28 and downregulation of ARHGEF6 inhibits cell spreading and adhesion. 27 Reduction of expression in Cbl cos may act downstream of DNA repair signaling and help to signal cells to maintain excess ROS, to stop proliferation and further adhesion of cells. Physical interaction of DNA-PKc with ARHGEF6, implicating extensive DNA damage, may signal for cell-cycle inhibition, spreading and apoptosis regulation in Cbl cos -treated cells. Interaction of DNA-PKc with p53 has also been earlier shown in fibroblast and glioma cells. 40, 41 However, interaction of DNA-PKc with p53 is observed in both the nucleus and the cytoplasm of Cbl cos cells, but only in the nucleus of Cbltreated cells. Although both are predominantly nuclear proteins, it is possible that both are extruded from the nucleus in response to COS treatment and will move to the cytoplasm or more precisely to the mitochondria. Several reports suggest that DNA-PKc exists in the cytoplasm in mitotic phase. 42, 43 Although p53 is predominantly a nuclear protein, it also travels from the nucleus to the mitochondria in response to death stress. 44 Moreover, it seems that, in dividing Cbl cos cells, DNA-PKc is more in the nucleus than in the cytoplasm, whereas in dying cells (in which the nucleus appears fragmented, a sign of late-stage apoptosis), it is present more in the cytoplasm (data not shown). The much lesser expression of cyclin-dependant kinase, CDK6, in Cbl cos cells also justifies apoptotic signaling in these cells. The reduced expression of CDK6 inhibits cell-cycle progression and proliferation 45 in erythrocyte progenitor cells, supporting the underlying mechanism that CDK6 action may be similar for these two types of cells.
The DNA damage signaling for apoptosis can also be attributed to a higher expression of p52, a TFIIH transcription factor having a death domain that is involved in transcription of proapoptotic proteins and in activation of cell death. 46, 47 The higher level of NF-kB2 transcripts and proteins in Cbl cos cells than in Cbl-treated cells may have a significant role in activating apoptosis.
Increase in TRAF3, a TNF receptor molecule, can generate ROS through NADPH oxidase and induce JNK-mediated apoptosis. TRAF3 can bind to nucleoporin in the nuclear membrane, facilitating the transport of the signaling molecule either way. 48 In A2780/100 cells, TRAF3 transcripts are increased under Cbl cos treatment and increase of its expression at 1 h may be significant for the translocation of the signaling molecule across those membranes. Subsequently, HSP70 sequesters antiapoptotic proteins (Bcl2, bcl2l1) in the cytoplasm and transports them to the mitochondria. 32 Reduction of its expression in mRNA and protein levels also supports its role in the activation of cell death in Cbl cos -treated cells and suggests that its role in drug resistance is similar to that of pancreatic cancer cells, in which depletion of HSP70 induces apoptosis. 49 Changes in mitochondrial membrane permeability with the Ca 2 þ pool of inner mitochondria and cytochrome c release are a necessary prerequisite for apoptotic signaling. A subsequent increase in CACNA2D2, a mitochondrial Ca 2 þ pool regulator, 50 and a decrease in BCL2L1 in transcript and protein levels (data not shown) may explain apoptotic signaling to mitochondria. Figure 2B) , especially ATP-dependent membrane proteins, may have a significant role in Cbl sensitivity in Cbl cos cells. The association of drug resistance with P-gp (p-glycoprotein) and MRP (MDR-associated protein) remains to be tested, as they modulate drug sensitivity in some resistant cancer cells. 54, 55 In contrast, modulation of ROS-sensitive guanine exchange factor (ARHGEF6) may hold the key for increasing sensitivity of Cbl in A2780/100-resistant cells. In fact, preliminary results show that siRNA knockdown in resistant cells increases the sensitivity of resistant cells (data not shown). Nevertheless, low doses (100 mM) of Cbl (15 mg daily 56 or 0.1 mg kg À1 body weight for 4 days 57 is mostly used in patients) with very low doses (10 ng ml À1 , 0.0026 U ml
À1
; for cytotoxicity, it is generally used in high doses such as 0.1-1 U ml À1 58 and in rat hepatocytes 0.4 U ml À1 59 ) of COS are useful for increasing drug sensitivity in A2780 ovarian carcinoma cells. Successful potential application of COS in conjunction with Cbl may hold potential for inhibition of tumor progression and can be tested in a mouse model for subsequent development of chemotherapy of ovarian cancer.
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